Picture supply: Getty Photos
Penny shares are sometimes dangerous investments. Nevertheless, it is price contemplating a small allocation to those shares, as they will present enormous returns in some instances.
Right here, I might wish to deal with penny shares that Citi analysts at the moment have a really bullish view on. At present buying and selling at simply 13.8p, which means you should buy round 7,200 shares for £1,000.
Healthcare changer
In the present day’s featured shares are: creo medical (LSE: Cleo). An revolutionary medical gadget firm specializing in endoscopic (minimally invasive) surgical devices.
The corporate’s merchandise embody the Speedboat Inject, a multimodal endoscopic instrument that surgeons can use to dissect, minimize, inject, seal, and so forth. throughout surgical procedure on pre-cancer and most cancers sufferers, and the Speedboat Ultraslim, a low-profile model designed to succeed in deep/slender spots within the gastrointestinal tract. These merchandise permit surgeons to carry out complicated procedures fully via an endoscope, probably permitting sufferers to keep away from in depth surgical procedure.
Anticipate a wild journey
Now, this can be a very small firm. Its market capitalization at the moment stands at simply £59m. Corporations of this measurement are typically dangerous investments, as inventory costs are inclined to fluctuate broadly attributable to a scarcity of buying and selling liquidity.
In addition they typically have new applied sciences which can be unproven and unprofitable at scale. And that is the case right here. It is a comparatively new know-how and the corporate isn’t making a revenue on it.
However analysts are very bullish on Creomedical. The typical value goal is at the moment 40p, representing round 190% above the present share value.
Attaining robust efficiency in 2025
Analysts’ value targets needs to be taken with a grain of salt, however it’s comprehensible why they’re bullish right here. Cleo has momentum proper now.
In direction of 2025:
- Continued medical adoption of the product resulted in income up 50% 12 months on 12 months to £6m (second half income up 58%).
- Value controls decreased underlying working prices by 20% to £18.4m.
- The money stability on the finish of the 12 months was £12.4m, in contrast with £8.7m in the identical interval final 12 months.
Vital progress anticipated in 2026
Relating to the long run, the corporate says that the outlook for fiscal 2026 and past is brilliant. This 12 months, we anticipate continued quarter-on-quarter progress as we enhance operational effectivity.
“Strategically, our merchandise are well-positioned in a rising and enticing market, providing vital potential for shareholder returns.”
Cleo Medical Chair Kevin Crofton
It is price noting that analysts at the moment anticipate Creo to generate income of £10.2m this 12 months. There isn’t any assure the corporate will be capable to hit this quantity, but when it did, it might enhance gross sales by a whopping 70%.
Is there an funding alternative right here?
So, is that this penny inventory price a more in-depth look? I feel so. It isn’t a inventory I might go “all in” on. There are a variety of dangers and you possibly can find yourself going bankrupt. Nevertheless, we expect there’s a variety of potential on the present share value. For my part, that is price additional analysis.